Compare Regeneron Pharmaceuticals Inc (REGN) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs TeraWulf Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while TeraWulf Inc trades at $17.15 (market cap $8.91B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 9.4× TeraWulf Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| REGN | WULF | |
|---|---|---|
Market Cap | $83.43B | $8.91B |
Sector | Health | Technology |
52-Week High | $852.03 | $28.98 |
52-Week Low | $555.51 | $10.49 |
Enterprise Value | $78.14B | $11.53B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
WULF trades at $17.86, up 8.18% today, amid a bullish technical signal despite mixed moving averages. The company reported a net loss of $661.42M in 2025 with a negative net margin of -1,179.94%, though revenue was $168.46M. Recent news highlights its pivot to AI data centers, including a Kentucky power agreement approval (GlobeNewsWire, 2026-08-24).
Analyst consensus is strongly bullish with a $35.94 price target, but high valuation ratios and persistent losses pose risks. Investment opportunity hinges on successful execution of AI infrastructure expansion, while risks include cash burn and competitive pressures in the data center space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
